Bevacizumab in recurrent WHO grades II-III glioma.
Annakib S, Rigau V, Darlix A, Gozé C, Duffau H, Bauchet L, Jarlier M, Fabbro M.
Annakib S, et al. Among authors: goze c.
Front Oncol. 2023 Jul 18;13:1212714. doi: 10.3389/fonc.2023.1212714. eCollection 2023.
Front Oncol. 2023.
PMID: 37534252
Free PMC article.